1st production QuiremSpheres

On May 21st, the first patient dosis of QuiremSpheres was processed at RTM and then shipped to the stituto Nazionale dei Tumori hospital in Milan, Italy. There it was used for the treatment of a patient suffering from hepatocellular carcinoma (HCC). QuiremSpheres® are radioactive microspheres for SIRT and are based on the isotope holmium-166. 

Voor meer informatie: http://www.quirem.com/

1st production QuiremSpheres

Other news

Cooperation RTM-Alliance Medical

Cooperation RTM-Alliance Medical

It is with great pleasure that we announce our cooperation with Alliance Medical Group (AMG) regardi...

Read more

First liver cancer patient treated with microspheres irradiated in TU Delft

First liver cancer patient treated with microspheres irradiated in TU Delft

Radboud Translational Medicine will perform the dispensing of below product. The production and dis...

Read more

RTM supports Citryll’s imaging trial of [89Zr]Zr-DFO-CIT-013

RTM supports Citryll’s imaging trial of [89Zr]Zr-DFO-CIT-013

Radboud Translational Medicine (RTM) is proud to announce its role as manufacturing partner for the...

Read more

RTM added as distributor NeuraCeq®

RTM added as distributor NeuraCeq®

Exciting news! Life Molecular Imaging’s NeuraCeq® 300 MBq/ml solution for injection (florbetaben 18F...

Read more

Interested in a collaboration?

Contact us to discuss the possibilities.